Viewing Study NCT06746961

Home Icon Home Search Icon Search Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs
Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug
Ignite Creation Date: 2025-12-24 @ 11:52 AM
Ignite Modification Date: 2026-01-31 @ 6:59 PM
Study NCT ID: NCT06746961
Status: NOT_YET_RECRUITING
Last Update Posted: 2024-12-24
First Post: 2024-12-19
Is NOT Gene Therapy: True
Has Adverse Events: False
Brief Title: Efficacy and Safety of QL1706 Plus Lenvatinib As 2nd Line Theapy in Patients with Metastatic Esophageal Carcinoma After Disease Progression on ICIs Therapy
Sponsor: The First Affiliated Hospital of Zhengzhou University
Organization:
Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Esophageal Squamous Cell Carcinoma (ESCC) View
Keywords:

Keywords

Keyword Brief Keyword Text View
None QL1706 View
None lenvatinib View
None immune checkpoint blockades View
None esophageal squamous cell carcinoma View
None ESCC View